EssilorLuxottica Société anonyme
EssilorLuxottica sells lenses, frames and, separately, the optical shops where they are bought. Ray-Ban and Oakley are its brands. Chanel and Prada, if they are there, are licenses that can end. Hoya and Zeiss sell lenses. The independent optician also sells glasses. It is not a monopoly of vision and it is not an integration that cannot be left. This report does not describe how the lens is made.
The prescription lens and the sunglass do not move together. The customer can buy the frame in one place and the lens in another. A year of heavy fashion is not normal earnings.
Cash separates those books. The dividend has to fit. It is not a chain that closes the prescription.
"The advantage is the shop that already sells that lens and the frame the customer already recognizes. They can buy somewhere else. The moat narrows if the license ends, or if fashion falls and the prescription does not make it up."
Loading the Vaultflake…
—
Health is the debt of several books, lens, frame and store, not of a monopoly. Quality separates the prescription-lens margin from the sunglass. Growth follows pairs sold, not a year of heavy fashion. P/E is read against that year, not against that peak as normal. Shareholder return is the dividend, checked against cash. Do not read it as vision already closed.
The P/E of a year of heavy fashion is not the earnings if sunglasses soften. EV/EBITDA is read without treating the license as if the brand were owned forever. Do not use a single optician's multiple as if the lens and the store were the same book. A dash if the EL.PA cache is cold.
Not advice on EssilorLuxottica. Vaultflake does not treat the group as a monopoly and does not describe how the lens is made. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.
The advantage is the shop that already sells that lens and the frame the customer already recognizes. They can buy somewhere else. The moat narrows if the license ends, or if fashion falls and the prescription does not make it up.
Health is the debt of several books, lens, frame and store, not of a monopoly. Quality separates the prescription-lens margin from the sunglass. Growth follows pairs sold, not a year of heavy fashion. P/E is read against that year, not against that peak as normal. Shareholder return is the dividend, checked against cash. Do not read it as vision already closed.
The P/E of a year of heavy fashion is not the earnings if sunglasses soften. EV/EBITDA is read without treating the license as if the brand were owned forever. Do not use a single optician's multiple as if the lens and the store were the same book. A dash if the EL.PA cache is cold.
Not advice on EssilorLuxottica. Vaultflake does not treat the group as a monopoly and does not describe how the lens is made. Read the filings. A past dividend is not a right. The table is a snapshot, not a target price.
Health Care · Pharmaceuticals and Medical Devices
Health Care · Diabetes and Obesity Medicines
Health Care · Insurance and Optum
Health Care · Diabetes and Obesity Medicines
Health Care · Immunology
Health Care · Oncology
A free account opens the interactive chart. The Vault assistant is Premium.